Severe Soft Tissue Infections

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 571-591

  Napolitano, Lena M ^a  

^a (Trauma Burns Critical Care Emergency Surgery)   (United States)

Author keywords

Abscess; Antimicrobial therapy; Debridement; Drainage; Methicillin resistant S aureus; Necrotizing soft tissue infections; Skin infections; Soft tissue infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFALEXIN; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; ICLAPRIM; IMMUNOGLOBULIN; LINEZOLID; ORITAVANCIN; RIFAMPICIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABSCESS DRAINAGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; FLUID RESUSCITATION; HUMAN; HYPERBARIC OXYGEN; INFECTION CONTROL; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL IDENTIFICATION; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NECROTIZING SOFT TISSUE INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PYOMYOSITIS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; VACUUM ASSISTED CLOSURE;

ANTI-BACTERIAL AGENTS; DEBRIDEMENT; DRAINAGE; HUMANS; INTENSIVE CARE UNITS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 68049133323     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.006     Document Type: Review

References (100)

1. Napolitano L.M. The diagnosis and treatment of skin and soft tissue infections (SSTIs). Surg Infect 9 Suppl 1 (2008) s17-s27
2. DiNubile M.J., and Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 53 Suppl 2 (2004) ii37-ii50
3. Vinh D.C., and Embil J.M. Severe skin and soft tissue infections and associated critical illness. Curr Infect Dis Rep 9 5 (2007) 415-421
4. May A.K. Skin and soft tissue infections. Surg Clin North Am 89 2 (2009) 403-420
5. Chan T., Yaghoubian A., Rosing D., et al. Low sensitivity of physical examination findings in necrotizing soft tissue infection is improved with laboratory values: a prospective study. Am J Surg 196 6 (2008) 926-930 [discussion: 930]
6. Wall D.B., deVirgilio C., Black S., et al. Objective criteria may assist in distinguishing necrotizing fasciitis from non-necrotizing soft tissue infection. Am J Surg 179 11 (2000) 17-21
7. Wall D.B., Klein S.R., Black S., et al. A simple model to help distinguish necrotizing fasciitis from non-necrotizing soft tissue infections. J Am Coll Surg 191 3 (2000) 227-231
8. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
9. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
10. Garnacho-Montero J. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31 (2003) 2742-2751
11. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 22 (1996) 387-394
12. Ruhe J.J., Smith N., Bradsher R.W., et al. Community-onset methicillin-resistant Staphylococcus aureus skin and soft tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 44 (2007) 777-784
13. Schramm G.E., Johnson J.A., Doherty J.A., et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 34 8 (2006) 2069-2074
14. Chuck E.A., Frazee B.W., Lambert L., et al. The benefit of empiric treatment for MRSA. J Emerg Med (2008) in press
15. Gorwitz R.J., Jernigan D.B., Powers J.H., et al. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at:. http://198.246.98.21/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf Accessed April 17, 2009
16. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 6 (2006) 1589-1596
17. Brook I. Microbiology and management of soft tissue and muscle infections. Int J Surg 6 4 (2008) 328-338
18. Naimi T.S., LeDell K.H., Como-Sabetti K., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
19. Crum N.F., Lee R.U., Thornton S.A., et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 119 (2006) 943-951
20. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 355 7 (2006) 666-674
21. Miller L.G., Perdreau-Remington F., Rieg G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352 14 (2005) 1445-1453
22. Frazee B.W., Lynn J., Charlebois E.D., et al. High prevalence of methicillin-resistance in emergency department skin and soft tissue infection. Ann Emerg Med 45 (2005) 311-320
23. King M.D., Humphrey B.J., and Wang Y.F. Emergence of community acquired methicillin-resistant Staphylococcus aureus USA 300 Clone as the predominant cause of skin and soft tissue infections. Ann Intern Med 144 (2006) 309-317
24. Awad S.S., Elhabash S.I., Lee L., et al. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft tissue infections: reconsideration of empiric antimicrobial therapy. Am J Surg 194 (2007) 606-610
25. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 166 (2006) 2138-2144
26. Howden B.P., Ward P.B., Charles P.G.P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
27. Lipsky B.A., Weigelt J.A., Gupta V., et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 28 11 (2007) 1290-1298
28. Stevens D.L., Bisno A.L., Chambers H.F., et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin Infect Dis 41 10 (2005) 1373-1406
29. Dietrich D.W., Auld D.B., and Mermel L.A. Community-acquired methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics 113 4 (2004) e347-e352
30. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
31. Adcock P.M., Pastor P., Medley F., et al. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 178 (1998) 577-580
32. Shahin R., Johnson I.L., Jamieson F., et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Arch Pediatr Adolesc Med 153 (1999) 864-868
33. Lee N.E., Taylor M.M., Bancroft E., et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 40 (2005) 1529-1534 [erratum, Clin Infect Dis 2005;41:135]
34. Ellis M.W., Hospenthal D.R., Dooley D.P., et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 39 (2004) 971-979
35. Aiello A.E., Lowy F.D., Wright L.N., et al. Methicillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis 6 (2006) 335-341
36. Kazakova S.V., Hageman J.C., Matava M., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352 (2005) 468-475
37. Groom A.V., Wolsey D.H., Naimi T.S., et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 286 (2001) 1201-1205
38. Castrodale L.J., Beller M., and Gessner B.D. Over-representation of Samoan/Pacific Islanders with methicillin-resistant Staphylococcus aureus (MRSA) infections at a large family practice clinic in Anchorage, Alaska, 1996-2000. Ala Med 46 (2004) 88-91
39. Szumowski J.D., Cohen D.E., Kanaya F., et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51 (2007) 423-428
40. Skiest D.J., Brown K., Cooper T.W., et al. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect 54 (2007) 427-434
41. Young D.M., Harris H.W., Charlebois E.D., et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 139 (2004) 947-953
42. Napolitano L.M. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 9 Suppl 1 (2008) S15-S27
43. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195 (2007) 202-211
44. Wang R., Braughton K.R., Kretschmer D., et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13 12 (2007) 1510-1514
45. Filbin M.R., Ring D.C., Wessels M.R., et al. Case 2-2009: a 25 year-old man with pain and swelling of the right hand and hypotension. N Engl J Med 360 (2009) 281-290
46. Marshall J.C., Maier R.V., Jimenez M., et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32 Suppl 11 (2004) S513-S526
47. Laterre P.F. Progress in medical management of intra-abdominal infections. Curr Opin Infect Dis 21 4 (2008) 393-398
48. Kuo D.C., Chasm R.M., and Witting M.D. Emergency department physician ability to predict methicillin-resistant Staphylococcus aureus skin and soft tissue infections. J Emerg Med (2008) in press
49. Stryjewski M.E., and Chambers H.F. Skin and soft tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5 (2008) S368-S377
50. Sarani B., Strong M., Pascual J., et al. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg 208 2 (2009) 279-288
51. Anaya D.A., and Dellinger E.P. Necrotizing soft tissue infection: diagnosis and management. Clin Infect Dis 44 5 (2007) 705-710
52. Cainzos M., and Gonzalez-Rodriguez F.J. Necrotizing soft tissue infections. Curr Opin Crit Care 13 4 (2007) 433-439
53. Yilmazlar T., Ozturk E., Alsoy A., et al. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg 31 9 (2007) 1858-1862
54. Cuschieri J. Necrotizing soft tissue infection. Surg Infect (Larchmt) 9 6 (2008) 559-562
55. Anaya D.A., McMahon K., Nathens A.B., et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 140 (2005) 151-157
56. Wong C.H., Khin L.W., Heng K.S., et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 32 7 (2004) 1535-1541
57. Su Y.C., Chen H.W., Hong Y.C., et al. Laboratory risk indicator for necrotizing fasciitis score and the outcomes. ANZ J Surg 78 11 (2008) 968-972
58. Struk D.W., Munk P.L., Lee M.J., et al. Imaging of soft tissue infections. Radiol Clin North Am 39 2 (2001) 277-303
59. Brothers T.E., Tagge D.U., Stutley J.E., et al. Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J Am Coll Surg 187 (1998) 416-421
60. Wong C.H., Chang H.C., Pasupathy S., et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 85 8 (2003) 1454-1460
61. McHenry C.R., Piotrowski J.J., Petrinic D., et al. Determinants of mortality for necrotizing soft tissue infections. Ann Surg 221 5 (1995) 558-565
62. Elhabash S, Lee L, Farrow B, et al. Characteristics and microbiology of patients presenting with necrotizing fasciitis. Presented at the Association of VA Surgeons 31st Annual Meeting. Little Rock, Arkansas, May 10-12, 2007.
63. Lee T.C., Carrick M.M., Scott B.G., et al. Incidence and clinical characteristics of MRSA necrotizing fasciitis in a large urban hospital. Am J Surg 194 6 (2007) 809-812
64. Young L.M., and Price C.S. Community-acquired MRSA emerging as an important cause of necrotizing fasciitis. Surg Infect (Larchmt) 9 4 (2008) 469-474
65. Olsen R.J., Burns K.M., Chen L., et al. Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by MRSA. J Clin Microbiol 46 3 (2008) 1144-1147
66. Dehority W., Wang E., Vernon P.S., et al. Community-associated MRSA necrotizing fasciitis in a neonate. Pediatr Infect Dis J 25 11 (2006) 1080-1081
67. Tsai Y.H., Hsu R.W., Huang T.J., et al. Necrotizing soft tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am 89 3 (2007) 631-636
68. Tsai Y.H., Hsu R.W., Huang K.C., et al. Systemic Vibrio infection presenting as necrotizing fasciitis and sepsis. A series of 13 cases. J Bone Joint Surg Am 86 11 (2004) 2497-2502
69. Minnaganti V.R., Patel P.J., Iancu D., et al. Necrotizing fasciitis caused by Aeromonas hydrophila. Heart Lung 29 4 (2000) 306-308
70. Bross M.H., Soch K., Morales R., et al. Vibrio vulnificus infection. diagnosis and treatment. Am Fam Physician 76 4 (2007) 539-544
71. Tsai Y.H., Huang T.J., Hsu R.W., et al. Necrotizing soft tissue infections and primary sepsis caused by Vibrio vulnificus and Vibrio cholerae non-O1. J Trauma 66 3 (2009) 899-905
72. Kuo Y.L., Shieh S.J., Chiu H.Y., et al. Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment, and prevention. Eur J Clin Microbiol Infect Dis 26 11 (2007) 785-792
73. Huang W.S., Hsieh S.C., Hsieh C.S., et al. Use of vacuum-assisted wound closure to manage limb wounds in patients suffering from acute necrotizing fasciitis. Asian J Surg 29 3 (2006) 135-139
74. Steinstraesser L., Sand M., and Steinaue H.U. Giant VAC in a patient with extensive necrotizing fasciitis. Int J Low Extrem Wounds 8 1 (2009) 28-30
75. Silberstein J., Grabowski J., and Parsons J.K. Use of a vacuum-assisted device for Fournier's gangrene: a new paradigm. Rev Urol 10 1 (2008) 76-80
76. Ozturk E., Ozquc H., and Yilmazlar T. The use of vacuum-assisted closure therapy in the management of Fournier's gangrene. Am J Surg 197 (2009) 660-665
77. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28 (1999) 800-807
78. Lamothe F., D'Amico P., Ghosn P., et al. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 21 (1995) 1469-1470
79. Alejandria M.M., Lansang M.A., Dans L.F., et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 1 (2002) CD001090
80. Darabi K., Abdel-Wahab O., and Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46 (2006) 741-753
81. Schrage B., Duan G., Yang L.P., et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 43 (2006) 743-746
82. George M.E., Rueth N.M., Skarda D.E., et al. Hyperbaric oxygen does not improve outcome in patients with necrotizing soft tissue infection. Surg Infect (Larchmt) 10 1 (2009) 21-28
83. Brown D.R., Davis N.L., Lepawsky M., et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 167 (1994) 485-489
84. Shupak A., Shoshani O., Golderberg I., et al. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy?. Surgery 118 (1995) 873-878
85. Korhonen K. Review Hyperbaric oxygen therapy in acute necrotizing infections. With a special reference to the effects on tissue gas tensions. Ann Chir Gynaecol 89 (2000) 7-36
86. Mindrup S.R., Kealey G.P., and Fallon B. Hyperbaric oxygen for the treatment of fournier's gangrene. J Urol 173 (2005) 1975-1977
87. Brook I. Microbiology and management of myositis. Int Orthop 28 5 (2004) 257-260
88. Garcia J. MRI in inflammatory myopathies. Skeletal Radiol 29 (2000) 425-438
89. Lipsky B.A., Berendt A.R., Deery H.G., et al. Infectious Diseases Society of America. Clin Infect Dis 39 7 (2004) 885-910
90. Lavery L.A., Armstrong D.G., Murdoch D.P., et al. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis 44 4 (2007) 562-565
91. Weigelt J., Itani K., Stevens D., et al. Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
92. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 38 (2004) 1673-1681
93. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
94. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415
95. Stryjewski M.E., Graham D.R., Wilson S.E., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by gram-positive organisms. Clin Infect Dis 46 11 (2008) 1683-1693
96. Giamarellou H, O'Riordan W, Harris H, et al. Phase 3 trial comparing 3-7 days of oritavancin versus 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003.
97. Noel G.J., Strauss R.S., Amsler K., et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 52 (2008) 37-44
98. Noel G.J., Bush K., Bagchi P., et al. A randomized, double-blind trial comparing ceftobiprole medocaril to vancomycin plus ceftazidime in the treatment of patients with complicated skin and skin structure infection. Clin Infect Dis 46 (2008) 647-655
99. ASSIST-1 and ASSIST-2 (Arpida's Skin and Skin Structure Infection Studies). Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting. Washington, DC, 2008.
100. Corey R, Wilcox M, Talbot GH, et al. CANVAS-1. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC, 2008.